These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6320298)

  • 41. Influence of prelimbic and sensorimotor cortices on striatal neurons in the rat: electrophysiological evidence for converging inputs and the effects of 6-OHDA-induced degeneration of the substantia nigra.
    Florio T; Di Loreto S; Cerrito F; Scarnati E
    Brain Res; 1993 Aug; 619(1-2):180-8. PubMed ID: 8374776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems.
    Koob GF; Simon H; Herman JP; Le Moal M
    Brain Res; 1984 Jun; 303(2):319-29. PubMed ID: 6430466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central monoaminergic pathways with emphasis on their relation to the so called 'extrapyramidal motor system'.
    Fuxe K; Hökfelt T; Olson L; Ungerstedt U
    Pharmacol Ther B; 1977; 3(2):169-210. PubMed ID: 413120
    [No Abstract]   [Full Text] [Related]  

  • 44. Altered mesoaccumbens and nigro-striatal dopamine physiology is associated with stereotypy development in a non-rodent species.
    McBride SD; Hemmings A
    Behav Brain Res; 2005 Apr; 159(1):113-8. PubMed ID: 15795004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression.
    Hung HC; Lee EH
    Brain Res Mol Brain Res; 1996 Sep; 41(1-2):14-26. PubMed ID: 8883930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brain chemistry and behaviour.
    Iversen SD
    Psychol Med; 1980 Aug; 10(3):527-39. PubMed ID: 7443906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat.
    Oakley NR; Hayes AG; Sheehan MJ
    Psychopharmacology (Berl); 1991; 105(2):204-8. PubMed ID: 1686655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of striatal drug infusions.
    Tepper JM; Nakamura S; Young SJ; Groves PM
    Brain Res; 1984 Sep; 309(2):317-33. PubMed ID: 6089960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of neurotensin and immunneutralization with anti-neurotensin-serum on dopaminergic-cholinergic interaction in the striatum.
    Töröcsik A; Rakovska A; Görcs T; Vizi ES
    Brain Res; 1993 May; 612(1-2):306-12. PubMed ID: 8101133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neurophysiologic and pharmacologic evidence of autoregulationin the nigrostriatal system].
    Arushanian EB; Tolpyshev BA
    Biull Eksp Biol Med; 1981 Feb; 91(2):133-6. PubMed ID: 7194700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Participation of the nigro-striatal and mesolimbic dopaminergic systems of the brain in the control of components of learned motor reactions in the dog].
    Shapovalova KB; Iakimovskiĭ AF
    Fiziol Zh SSSR Im I M Sechenova; 1987 May; 73(5):579-89. PubMed ID: 3040479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lesions of the nigro-striatal dopamine pathway: effects on the storage and metabolism of striatal dopamine.
    Goldstein M; Ceasar P; Anagnoste B
    Pharmacol Ther B; 1976; 2(1):89-95. PubMed ID: 131326
    [No Abstract]   [Full Text] [Related]  

  • 54. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of blocking dopamine release on synthesis rate of dopamine in the striatum of the rat.
    Van Zwieten-Boot BJ; Noach EL
    Eur J Pharmacol; 1975; 33(2):247-54. PubMed ID: 171162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 57. Dopamine agonist-induced restoration of drinking in response to hypertonic saline in adipsic dopamine denervated rats.
    Dourish DT; Jones RS
    Brain Res Bull; 1982 Apr; 8(4):375-9. PubMed ID: 6807495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The place of dopamine in the cortico-basal ganglia circuit.
    Haber SN
    Neuroscience; 2014 Dec; 282():248-57. PubMed ID: 25445194
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychoneuroendocrine effects of neurotoxic lesions in the septum and striatum of rats.
    Nance DM
    Pharmacol Biochem Behav; 1983 Apr; 18(4):605-9. PubMed ID: 6408652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlations of motility, defecatory behavior and striatal dopaminergic activity in rats.
    Pradhan N; Arunasmitha S
    Physiol Behav; 1991 Jul; 50(1):135-8. PubMed ID: 1946705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.